Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 37, 2018 - Issue 5
Submit an article Journal homepage
264
Views
10
CrossRef citations to date
0
Altmetric
Case Report

Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma

Reem AlnabulsiDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7998-2841
ORCID Icon,
Ahsen HussainDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
&
Dan DeAngelisDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
Pages 381-384 | Received 09 May 2017, Accepted 29 Dec 2017, Published online: 30 Jan 2018

References

  • Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–594. Epub 2001/03/13. doi:10.1146/annurev.immunol.19.1.565.
  • McElnea E, Ni Mhealoid A, Moran S, Kelly R, Fulcher T. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit. 2014;33:424–427. (1744-5108 (Electronic)). doi:10.3109/01676830.2014.949792.
  • Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunothe (Hagerstown, Md: 1997). 2005;28(6):593–598. Epub 2005/ 10/15. doi:10.1097/01.cji.0000178913.41256.06.
  • Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. Epub 2010/ 06/08. doi:10.1056/NEJMoa1003466.
  • Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–381. Epub 2014/ 03/13. doi:10.1530/ERC-13-0499.
  • Borodic GE, Hinkle DM. Reply Re: “Drug-induced Graves disease from CTLA-4 receptor suppression”. Ophthal Plast Reconstr Surg. 2013;29(3):241. Epub 2013/ 05/09. doi:10.1097/IOP.0b013e31828957c3.
  • Lecouflet M, Verschoore M, Giard C, et al. Orbital myositis associated with ipilimumab. Melanoma Research. 2011; 21:e24. (0151-9638 (Print)). doi:10.1097/01.cmr.0000399475.01484.56.
  • Bahn RS. Graves’ Ophthalmopathy. N Engl J Med. 2010;362(8):726–738. doi:10.1056/NEJMra0905750.
  • Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27(4):e87–e88. Epub 2011/01/19. doi:10.1097/IOP.0b013e3181ef72a1.
  • Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303–307. (1479-683X (Electronic)). doi:10.1530/EJE-10-0833.
  • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med. 2011;364(26):2517–2526. Epub 2011/06/07.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med. 2015;372(4):320–330. Epub 2014/11/18. doi:10.1056/NEJMoa1412082.
  • Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. Epub 2015/03/22. doi:10.1016/S1470-2045(15)70076-8.
  • Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Thromb. 2015;8(1):123. Epub 2015/ 11/01. doi:10.1186/s13045-015-0219-0.
  • Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO 4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32(5s):LBA9003. https://meetinglibrary.asco.org/record/92086/abstract
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med. 2015;373(1):23–34. Epub 2015/ 06/02. doi:10.1056/NEJMoa1504030.
  • Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Eng J Med. 2015;372(21):2006–2017. Epub 2015/ 04/22. doi:10.1056/NEJMoa1414428.
  • Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Eng J Med. 2013;369(2):122–133. Epub 2013/ 06/04. doi:10.1056/NEJMoa1302369.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.